

11-2015

Antimicrobial Resistance Patterns of Urinary Escheria Coli at an Australian Tertiary Hospital

Oyebola Fasugba

Australian Catholic University, oyebola.fasugba@acu.edu.au

Brett G. Mitchell

Avondale College of Higher Education, brett.mitchell@avondale.edu.au

George Mnatzaganian

Australian Catholic University, george.mnatzaganian@acu.edu.au

Anne Gardner

Australian Catholic University, anne.gardner@acu.edu.au

Follow this and additional works at: https://research.avondale.edu.au/nh_conferences



Part of the [Nursing Commons](#)

Recommended Citation

asugba, O., Mitchell, B. G., Mnatzaganian, G., & Gardner, A. (2015, November). *Antimicrobial resistance patterns of urinary escheria coli at an Australian tertiary hospital*. Poster presented at the International Australasian College of Infection Prevention and Control (ACIPC) Conference, Hobart, Australia.

This Conference Proceeding is brought to you for free and open access by the Faculty of Nursing and Health at ResearchOnline@Avondale. It has been accepted for inclusion in Nursing and Health Conference Papers by an authorized administrator of ResearchOnline@Avondale. For more information, please contact alicia.starr@avondale.edu.au.

Five-year antimicrobial resistance patterns of urinary *E. coli* at an Australian tertiary hospital

Oyebola Fasugba¹, Anne Gardner¹, George Mnatzaganian¹, Brett Mitchell^{1, 2}, Anindita Das³

¹Faculty of Health Sciences, Australian Catholic University

²Discipline of Nursing and Lifestyle Research Centre, Avondale College

³ACT Pathology, Canberra

Disclosure

- Ms Oyebola Fasugba, Prof Anne Gardner and A/Prof Brett Mitchell are members of ACIPC
- A/Prof Brett Mitchell is Interim Editor-in-Chief Infection, Disease and Health and Prof Anne Gardner is on the Editorial board
- A/Prof Brett Mitchell is a member of the scientific organising committee.
- Dr George Mnatzaganian has no conflicts of interests


Introduction

- >80% of urinary tract infections (UTIs) caused by *Escherichia coli* (*E. coli*) (Nicolle, 2008)
- Community acquired (CA) or hospital acquired (HA) classification
- Standard treatment is antibiotics (Stuck et al., 2012)
- Treatment based on local susceptibility patterns (Teoh et al., 2013)
- Inappropriate treatment leads to emergence of resistant pathogens & recurrence of infection (Trautner, 2010)




Introduction

- Evidence shows urinary *E. coli* is becoming increasingly resistant to common antimicrobials (WHO, 2014)
- Whilst prevalence rates for urinary *E. coli* resistance have been reported in Australia, available data do not adjust for age & sex
- To our knowledge there are no data comparing resistance patterns for CA and HA UTIs



Aims

- ❑ To describe the antimicrobial resistance patterns of *E. coli* UTI over five years (2009-2013) in patients at the Canberra Hospital
- ❑ Compare the prevalence of resistance in community-acquired and hospital-acquired *E. coli* UTI



Significance

- Expand understanding of antimicrobial resistance in urinary *E. coli* infections in Australia
- Contribute to ongoing surveillance data in the Australian Capital Territory (ACT)
- Potential for study findings to inform treatment decisions for UTI & influence therapy based on site of acquisition



Methods

- Ethics approval granted by ACT Health and ACU HREC
- Cross-sectional design
- Inclusions: Canberra Hospital samples; *E. coli* growth of $\geq 10^7$ cfu/L
- CA UTI: within 48 hours of admission; outpatients
- HA UTI: more than 48 hours after admission or within 48 hours of discharge



Methods

- Only the first positive *E. coli* culture per patient per year was included in analysis
- Overall 5-year and yearly antimicrobial resistance rates were calculated
- Rates compared between CA and HA UTIs
- Prevalence of Extended Spectrum Beta Lactamase (ESBL) producing *E.coli*
- Crude and adjusted time series analyses were conducted to assess resistance trends over the 5-year study period

Results

- 5346 positive *E. coli* UTIs belonging to 4744 patients
 - CA UTI → 84.3% (n=4505)
 - HA UTI → 15.7% (n=841)
- Mean age of all patients was 57.0 years (SD=27.6)
- 80.3% (n=3806) of patients were women
- Resistance highest for ampicillin (41.9%) & trimethoprim-sulphamethoxazole (32.7%)
- Resistance lowest for meropenem (0.1%) & gentamicin (4.0%)




Antimicrobial	5-year resistance %
Ampicillin	41.9
Trimethoprim-sulphamethoxazole	32.7
Trimethoprim	20.7
Norfloxacin	16.2
Ceftriaxone	13.5
Cephazolin	10.6
Piperacillin-tazobactam	10.3
Nalidixic acid	8.4
Nitrofurantoin	7.8
Amoxicillin-clavulanic acid	6.7
Ciprofloxacin	6.5
Gentamicin	4.0
Meropenem	0.1

Results

- Significantly higher resistance ($P < 0.05$) in HA compared to CA UTI for:
 - ✓ amoxicillin-clavulanate
 - ✓ cephalazolin
 - ✓ gentamicin
 - ✓ piperacillin-tazobactam
- ESBL-producing *E. coli* significantly higher ($P = 0.01$) in HA (3.0%; $n = 25$) compared with CA UTI (1.7%; $n = 75$)



Results



1=Summer
2=Autumn
3=Winter
4=Spring

Results

- Significant increase in resistance trend noted for all five antimicrobials ($P < 0.05$)
- Seasonal resistance pattern only significant for Trimethoprim ($P = 0.0056$)
- Regression analysis indicated a possible association between ciprofloxacin resistance and trimethoprim-sulphamethoxazole resistance with older age

Discussion

- Resistance rates lower than reported for single site studies in other countries (Ma et al., 2012; Perrin et al. 1999)
- High levels of ampicillin and trimethoprim-sulphamethoxazole resistance question their use as suitable empirical agents in the management of UTI in this population
- Differences in resistance for HA and CA UTI comparable with findings reported previously (Ma et al., 2012)



Discussion

- Presence of ESBL-producing *E. coli* in both HA and CA UTI pose significant public health concern
- Evidence to support findings of increase in resistance over time
- Seasonal trimethoprim resistance should be explored further
- Association between increasing age and antimicrobial resistance consistent with published literature (Blaettler et al. 2009)

Implications and Conclusion

- While resistance rates are lower than other studies, there is need for continuous resistance surveillance in the ACT
- Amoxicillin-clavulanate and nitrofurantoin still effective in this population
- Study findings will help inform UTI treatment guidelines
- Also provide baseline resistance data for future comparison and inform future interventions that can be evaluated



Acknowledgements

- ☐ Thanks to supervisors
- ☐ Thanks to Prof Peter Collignon (A/Exec Director, ACT Pathology), Ms Angelique Clyde-Smith (Senior Microbiology Scientist) and staff of ACT Pathology



References

- Blaettler, L., Mertz, D., Frei, R., Elzi, L., Widmer, A., Battegay, M., & Flückiger, U. (2009). Secular trend and risk factors for antimicrobial resistance in *Escherichia coli* isolates in Switzerland 1997–2007. *Infection*, 37(6), 534-539.
- Bouchillon, S. K., Badal, R. E., Hoban, D. J., & Hawser, S. P. (2013). Antimicrobial susceptibility of inpatient urinary tract isolates of Gram-negative bacilli in the United States: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program: 2009– 2011. *Clinical therapeutics*, 35(6), 872-877.
- Ma, K. L., & Wang, C. X. (2013). Analysis of the spectrum and antibiotic resistance of uropathogens in vitro: Results based on a retrospective study from a tertiary hospital. *American journal of infection control*, 41(7), 601-606.
- Nicolle, L. E. (2008). Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis. *Urologic Clinics of North America*, 35(1), 1-12.
- Perrin M, Donnio P, Heurtin-Lecorre C, Travert M, Avril J-L. Comparative antimicrobial resistance and genomic diversity of *Escherichia coli* isolated from urinary tract infections in the community and in hospitals. *Journal of Hospital Infection*. 1999;41(4):273-9.
- Stuck, A. K., Täuber, M. G., Schabel, M., Lehmann, T., Suter, H., & Mühlemann, K. (2012). Determinants of quinolone versus trimethoprim-sulfamethoxazole use for outpatient urinary tract infection. *Antimicrobial Agents and Chemotherapy*, 56(3), 1359-1363.
- Teoh, P., Basarab, A., Pickering, R., Ali, A., Hayes, M., & Somani, B. K. (2013). Changing trends in antibiotic resistance for urinary *E. coli* infections over five years in a university hospital. *Journal of Clinical Urology*.
- Trautner, B. W. (2010). Management of catheter-associated urinary tract infection (CAUTI). *Current opinion in infectious diseases*, 23(1), 76.
- World Health Organisation. (2014). *Antimicrobial resistance: global report on surveillance*.

Contact details

Bola Fasugba

Email: Oyebola.Fasugba2@myacu.edu.au